Comparative Perspective Retatrutide belongs to a newer generation of weight loss drugs that target three separate metabolic pathways
doi: 10.3389/fimmu.2024.1362501 Received 28 December 2023 Accepted 01 April 2024 Published 17 April 2024 Volume 15 - 2024 Edited by Sladjana Sobajic, University of Belgrade, Serbia Reviewed by Md Tajmul, National Institute of Diabetes and Digestive and Kidney Diseases (NIH), United States Jadranka Vranekovi, University of Rijeka, Croatia Updates Copyright 2024 Ramacieri, Locatelli, Semprini, Pelleri, Caracausi, Piovesan, Cicilloni, Vigna, Vitale, Sperti, Corvaglia, Pirazzoli, Strippoli, Catapano, Vione and Antonaros
The starting dose is explicitly not a place to live
The delivery arrived quickly with all necessary supplies included, and the all-in pricing structure is among the more transparent models weve reviewed
Alternative weight management approaches include specialist dietetic support, lifestyle interventions, alternative pharmacotherapy (with caution), or bariatric surgery with multidisciplinary assessment for suitable candidates
(3) Notably, only 53.8% of those prescribed a GLP-1 agonist in 2022 had a history of type 2 diabetes, highlighting a shifting clinical paradigm in which these agents are now widely used for obesity management and related metabolic disorders